Clareo Health | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
With
Astellas Pharma Inc
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Should have an established, confirmed diagnosis of Acute Myeloid Leukemia (AML) by World Health Organization (2016).
Should have failed at least 1 line of prior therapy (defined as failure to respond to therapy, and/or progression during or after therapy).
Should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
Should have adequate hematologic, kidney and liver function as described in the protocol.
For participants enrolling into the Expansion Cohort only: a documented FMS-like Tyrosine Kinase (FLT3) mutation in bone marrow or peripheral blood, as described in the protocol.
You may not be if
Has a diagnosis of acute promyelocytic leukemia (APL) or BCR-ABL-positive leukemia.
Has a history of other malignancies within 2 years prior to study entry, with exceptions as described in the protocol.
Has active central nervous system leukemia.
Has a history of chronic New York Heart Association (NYHA) class IV heart failure.
Has a corrected QT interval of \> 450 ms.
Has a chronic respiratory disease that requires continuous oxygen use.
